Table 2.
Top 3 drug combinations showing increased risk, based on LFDR values
| Drug_1 | Drug_2 | Drug_3 | Sample size |
|
Risk |
|---|---|---|---|---|---|
| Acetaminophen | Duloxetine | Hydrocodone | 2,439 | 231.392 | 0.309 |
| Acetaminophen | Oxycodone | Hydrocodone | 4,627 | 169.796 | 0.207 |
| Acetaminophen | Alprazolam | Hydrocodone | 4,983 | 162.596 | 0.199 |
| Acetaminophen | Duloxetine | Oxycodone | 1,169 | 140.429 | 0.352 |
| Acetaminophen | Hydrocodone | Zolpidem | 2,821 | 116.481 | 0.214 |
| Acetaminophen | Alprazolam | Oxycodone | 1,892 | 115.488 | 0.249 |
| Acetaminophen | Hydrocodone | Tramadol | 3,323 | 108.268 | 0.199 |
| Acetaminophen | Duloxetine | Tramadol | 768 | 95.622 | 0.359 |
| Duloxetine | Oxycodone | Hydrocodone | 692 | 84.164 | 0.354 |
| Acetaminophen | Alprazolam | Duloxetine | 785 | 81.757 | 0.324 |
Bold represents drug combinations reported for myopathy in SIDER 2.